Pacific Shuanglin Bio pharmacy Co Ltd (000403) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥70.28 Million ≈ $10.28 Million USD) by net assets (CN¥8.03 Billion ≈ $1.17 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pacific Shuanglin Bio pharmacy Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Pacific Shuanglin Bio pharmacy Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacific Shuanglin Bio pharmacy Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
0.025x |
|
Sichuan Crun Co Ltd
SHE:002272
|
-0.006x |
|
Arteche Lantegi Elkartea SA
MC:ART
|
0.249x |
|
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
|
0.063x |
|
Macmahon Holdings Ltd
AU:MAH
|
0.187x |
|
Sakura Development Co Ltd
TW:2539
|
0.185x |
|
Novavax Inc
NASDAQ:NVAX
|
0.224x |
|
Airport City Ltd
TA:ARPT
|
0.013x |
Annual Cash Flow Conversion Efficiency for Pacific Shuanglin Bio pharmacy Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Pacific Shuanglin Bio pharmacy Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see 000403 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
CN¥-215.99 Million ≈ $-31.61 Million |
-0.027x | -165.76% |
| 2024-12-31 | CN¥7.92 Billion ≈ $1.16 Billion |
CN¥321.79 Million ≈ $47.09 Million |
0.041x | -55.58% |
| 2023-12-31 | CN¥7.42 Billion ≈ $1.09 Billion |
CN¥679.01 Million ≈ $99.36 Million |
0.091x | +19.74% |
| 2022-12-31 | CN¥6.86 Billion ≈ $1.00 Billion |
CN¥524.22 Million ≈ $76.71 Million |
0.076x | +18.43% |
| 2021-12-31 | CN¥6.33 Billion ≈ $925.95 Million |
CN¥408.22 Million ≈ $59.74 Million |
0.065x | -67.99% |
| 2020-12-31 | CN¥966.91 Million ≈ $141.49 Million |
CN¥194.84 Million ≈ $28.51 Million |
0.202x | -15.36% |
| 2019-12-31 | CN¥801.60 Million ≈ $117.30 Million |
CN¥190.84 Million ≈ $27.93 Million |
0.238x | +26.45% |
| 2018-12-31 | CN¥619.48 Million ≈ $90.65 Million |
CN¥116.63 Million ≈ $17.07 Million |
0.188x | +393.01% |
| 2017-12-31 | CN¥558.88 Million ≈ $81.78 Million |
CN¥-35.91 Million ≈ $-5.26 Million |
-0.064x | -156.24% |
| 2016-12-31 | CN¥546.91 Million ≈ $80.03 Million |
CN¥62.49 Million ≈ $9.14 Million |
0.114x | -14.61% |
| 2015-12-31 | CN¥525.49 Million ≈ $76.90 Million |
CN¥70.31 Million ≈ $10.29 Million |
0.134x | -20.34% |
| 2014-12-31 | CN¥458.65 Million ≈ $67.11 Million |
CN¥77.04 Million ≈ $11.27 Million |
0.168x | -35.09% |
| 2013-12-31 | CN¥351.68 Million ≈ $51.46 Million |
CN¥91.01 Million ≈ $13.32 Million |
0.259x | -39.60% |
| 2012-12-31 | CN¥287.68 Million ≈ $42.10 Million |
CN¥123.24 Million ≈ $18.03 Million |
0.428x | -6.92% |
| 2011-12-31 | CN¥282.74 Million ≈ $41.37 Million |
CN¥130.14 Million ≈ $19.04 Million |
0.460x | +1176.66% |
| 2010-12-31 | CN¥274.00 Million ≈ $40.09 Million |
CN¥9.88 Million ≈ $1.45 Million |
0.036x | -95.56% |
| 2009-12-31 | CN¥137.64 Million ≈ $20.14 Million |
CN¥111.86 Million ≈ $16.37 Million |
0.813x | +92.34% |
| 2008-12-31 | CN¥177.26 Million ≈ $25.94 Million |
CN¥74.90 Million ≈ $10.96 Million |
0.423x | -95.59% |
| 2007-12-31 | CN¥9.92 Million ≈ $1.45 Million |
CN¥95.03 Million ≈ $13.91 Million |
9.578x | +2397.05% |
| 2006-12-31 | CN¥-27.16 Million ≈ $-3.97 Million |
CN¥-10.42 Million ≈ $-1.52 Million |
0.384x | -12.05% |
| 2005-12-31 | CN¥112.49 Million ≈ $16.46 Million |
CN¥49.06 Million ≈ $7.18 Million |
0.436x | +299.35% |
| 2004-12-31 | CN¥602.14 Million ≈ $88.11 Million |
CN¥-131.73 Million ≈ $-19.28 Million |
-0.219x | -271.64% |
| 2003-12-31 | CN¥840.33 Million ≈ $122.97 Million |
CN¥-49.47 Million ≈ $-7.24 Million |
-0.059x | -128.81% |
| 2002-12-31 | CN¥779.03 Million ≈ $114.00 Million |
CN¥159.18 Million ≈ $23.29 Million |
0.204x | +26.30% |
| 2001-12-31 | CN¥687.82 Million ≈ $100.65 Million |
CN¥111.28 Million ≈ $16.28 Million |
0.162x | +254.33% |
| 2000-12-31 | CN¥599.28 Million ≈ $87.69 Million |
CN¥27.36 Million ≈ $4.00 Million |
0.046x | +195.34% |
| 1999-12-31 | CN¥481.83 Million ≈ $70.51 Million |
CN¥-23.08 Million ≈ $-3.38 Million |
-0.048x | -326.45% |
| 1998-12-31 | CN¥235.63 Million ≈ $34.48 Million |
CN¥-2.65 Million ≈ $-387.22K |
-0.011x | -- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more